Introduction  This Fast Fact will discuss the use of interventions in hospice care that can be controversial due to high cost and/or uncertainty whether they constitute ‘palliative’ interventions. When a patient elects the Medicare Hospice Benefit (MHB), the patient, the doctor, and the hospice team develop a Plan of Care (POC) that lists a) the patient’s goals for care and b) the services needed to achieve these goals. A hospice program is fiscally responsible for all services outlined in the POC, and these services are paid for from the pool of money the hospice program gets from per diem payments (physician fees are billed separately – see Fast Fact #87).

Note: since there is no Medicare regulation that specifies what treatments are deemed ‘palliative,’ it is up to the individual hospice agency to determine whether or not they can financially and philosophically provide the interventions listed below. Most hospice agencies are not able to provide high-cost interventions due to financial limitations; patients may elect to be discharged from hospice care if they wish to pursue these options. Hospices with a large number of enrolled patients have greater financial resources and thus are better able to provide high-cost treatments. Recently, some hospices have introduced ‘open-access’ programs which more freely provide costly and even life-prolonging therapies to dying patients who would otherwise benefit from hospice services. The hope is that the increased costs will be covered by increased revenue from enrolling more patients earlier in the course of their illness.

Indications for use in Hospice Care  In general, the interventions listed below are potentially indicated in patients with a) a good functional status (up, out of bed > 50% of the time; Karnofsky Performance Status >50; ECOG ≤2 – see Fast Facts #13, 124), or b) a clear goal to be met (e.g. wedding anniversary in two weeks). These interventions are not indicated solely to assist patients or families psychologically cope with impending death – to give the impression that ‘something is being done.’

• Parenteral Fluids.  Indication: symptomatic dehydration where there is a patient-defined goal (e.g. upcoming family event). Fluids are not indicated to treat dry mouth or solely to reverse dehydration occurring as a normal aspect of the dying process; fluids may be of benefit to treat delirium in selected patients (see Fast Fact #133).

• Enteral feeding.  Indication: patient is hungry and there is a reason oral nutrition cannot be given (e.g. upper GI obstruction from esophageal cancer). See Fast Facts #10 and 84 for a complete review of the indications/contraindications for tube feeding.

• Total Parenteral Nutrition.  Indication: patient has short-gut syndrome or bowel obstruction and good functional status and a functional goal. See Fast Fact #190 for further discussion.

• Radiation Therapy.  Indication: symptoms of pain, bleeding, or neurological catastrophe (e.g. acute spinal cord compression) and the patient is expected to live long enough to experience benefit (> 4 weeks) and the potential benefits outweigh logistic burdens (e.g. travel to the radiotherapy site, getting on and off the treatment table). See Fast Facts # 66, 67.

• Red Blood Cell Transfusions or Erythropoietin.  Indication: Symptomatic anemia (dyspnea or fatigue) in ambulatory patients who demonstrate continued functional benefit from treatment.

• Platelet Transfusions.  Indication: active bleeding and severe thrombocytopenia (Platelet count < 10,000).

• Chemotherapy.  Indication: symptoms from the cancer are causing distress; the likelihood of effectiveness is high (expected Response Rate greater than 25% - see Fast Facts #14, 99); patient will live long enough to benefit (> 4-8 weeks, ECOG 0-2); and benefits outweigh burdens.

• Antibiotics.  Indication: oral antibiotics are appropriate to treat simple symptomatic infections (e.g. UTI). Parenteral antibiotics are not indicated unless there is an identified
susceptible organism, there is a clear functional goal to be met, the likelihood of successful
treatment is high, and the patient is expected to live long enough to achieve benefit.

• **Laboratory/Diagnostic services.** Indication: to monitor aspects of POC (e.g. warfarin
monitoring) or as part of a diagnostic evaluation for a new symptom for which the testing is
likely to substantially alter patient management. Note: diagnosis of a new problem that does
not relate to the terminal illness can be evaluated and treated by the patient’s primary care
provider under usual Medicare billing (e.g. acute myocardial infarction).

**References**

2. Wright AA, Katz IT. Letting go of the rope – aggressive treatment, hospice care, and
3. Marantz Henig R. Will we ever arrive at the good death? *New York Times.* August 7,

**Version History:** This *Fast Fact* was originally edited by David E Weissman MD. 2nd Edition was
version re-copy-edited April 2009; then again in June 2015.

**Fast Facts and Concepts** are edited by Sean Marks MD (Medical College of Wisconsin) and
associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous
support of a volunteer peer-review editorial board, and are made available online by the Palliative
Care Network of Wisconsin (PCNOW); the authors of each individual *Fast Fact* are solely
responsible for that *Fast Fact*’s content. The full set of *Fast Facts* are available at Palliative Care
Network of Wisconsin with contact information, and how to reference *Fast Facts.*

**Copyright:** All *Fast Facts and Concepts* are published under a Creative Commons Attribution-
NonCommercial 4.0 International Copyright ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)).
*Fast Facts* can only be copied and distributed for non-commercial, educational purposes. If you
adapt or distribute a *Fast Fact,* let us know!

**Disclaimer:** *Fast Facts and Concepts* provide educational information for health care
professionals. This information is not medical advice. *Fast Facts* are not continually updated, and
new safety information may emerge after a *Fast Fact* is published. Health care providers should
always exercise their own independent clinical judgment and consult other relevant and up-to-
date experts and resources. Some *Fast Facts* cite the use of a product in a dosage, for an
indication, or in a manner other than that recommended in the product labeling. Accordingly, the
official prescribing information should be consulted before any such product is used.